Pazopanib HCl (GW786034 HCl)

Catalog No.S1035

Pazopanib HCl (GW786034 HCl) Chemical Structure

Molecular Weight(MW): 473.98

Pazopanib HCl (GW786034 HCl) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFR, FGFR, c-Kit and c-Fms with IC50 of 10 nM, 30 nM, 47 nM, 84 nM, 74 nM, 140 nM and 146 nM in cell-free assays, respectively.

Size Price Stock Quantity  
In DMSO USD 191 In stock
USD 147 In stock
USD 270 In stock
USD 370 In stock

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

3 Customer Reviews

  • IC50 of Pazopanib that block ANDV-induced EC permeability. Endothelial cells were ANDV infected, and 3 days postinfection the permeability of cells in response to VEGF addition was determined in the presence or absence of increasing amounts of kinase inhibitor. (B): VEGFR2-Src inhibitors block ANDV-induced permeability. Endothelial cells were plated on vitronectin-coated Transwell inserts and infected at an MOI of 0.5 in triplicate with ANDV. Three days postinfection, the permeability of ANDV- and mock-infected endothelial cell monolayers was determined at indicated times in the presence or absence of Pazopanib.

    J Virol, 2011, 85(5): 2296-303. Pazopanib HCl (GW786034 HCl) purchased from Selleck.

    MRC5 non-transformed human lung fibroblasts were infected with influenza viruses (100 multiplicity of infection). Two hours after infection the cells were treated with vehicle control; sorafenib tosylate (2mM); pazopanib (2mM); OSU-03012 (2mM); and AR-13 (2mM). Twenty-four hours after infection the cells are treated with live/dead agent where green cells are viable and cells staining yellow or red are considered dead. Cells are examined at 10 magnification in a Hermes wide-field microscope (n¼3 SEM) P<0.05 less than vehicle control level of virus-mediated cell killing.

    J Cell Physiol, 2016, 231(10):2286-302.. Pazopanib HCl (GW786034 HCl) purchased from Selleck.

  • Effect of HDIL-2/TKI on apoptosis of RCC cells. Three RCC cell lines treated with different concentrations of Pazopanib and HDIL-2 and incubated for 48 h. Microscopic images show apoptotic materials 48 h following treatment (arrows show the apoptotic materials in the pazopanib-treated cells).

    Expert Opin Pharmacother 2014 15(11), 1489-99. Pazopanib HCl (GW786034 HCl) purchased from Selleck.

Purity & Quality Control

Choose Selective VEGFR Inhibitors

Click to view more

Notes:

2. For more details, such as half maximal inhibitory concentrations (IC50s) and working concentrations of each inhibitor, please click on the link of the inhibitor of interest.
3. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation.
4. Orange "√" refers to compounds which do inhibitory effects on the related isoform, but without specific value.

Biological Activity

Description Pazopanib HCl (GW786034 HCl) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFR, FGFR, c-Kit and c-Fms with IC50 of 10 nM, 30 nM, 47 nM, 84 nM, 74 nM, 140 nM and 146 nM in cell-free assays, respectively.
Features A multi-kinase inhibitor.
Targets
VEGFR1 [1]
(Cell-free assay)
VEGFR2 [1]
(Cell-free assay)
VEGFR3 [1]
(Cell-free assay)
FGFR [1]
(Cell-free assay)
PDGFR [1]
(Cell-free assay)
10 nM 30 nM 47 nM 74 nM 84 nM
In vitro

Pazopanib potently inhibits VEGF-induced phosphorylation of VEGFR2 in HUVEC cells with IC50 of 8 nM. [1] Pazopanib shows dose-dependent growth inhibition in all synovial sarcoma cell lines including SYO-1 and HS-SY-II cells. Proliferation of SYO-1 and HS-SY-II cells is inhibited even at 1 µg/mL of Pazopanib and is completely abolished at 5 µg/mL. Pazopanib induces G1 arrest, and thereby suppresses the growth of synovial sarcoma cells. Phosphorylation of Akts, GSK-3β, JNKs, p70 S6 Kinase, and mTOR is suppressed in Pazopanib-treated SYO-1 cells compared with that in the vehicle-treated cells. [2] Pazopanib between 20 m g/mL and 22.5 m g/mL shows an increasing reduction of RPE cell viability. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HUVEC NUT1bG5ST3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NWTER2V3cW6qaXLpeJMhfGinIG\FS2YucW6mdXPl[EBxem:uaX\ldoF1cW:wIH;mJGhWXkWFcx?= MVuxPFYzODN6Mh?=
HUVEC M{HofmtqdmG|ZTDhd5NigQ>? NFPIVXVqdmirYnn0d{BXTUeILXnu[JVk\WRicHjvd5Bpd3K7bHH0bY9vKG:oIG\FS2ZTNTJiaX6gTHVXTUNiY3XscJMhf2m2aDDhckBKSzVyIH;mJQKJxDhibl2= M2jP[|E5PjJyM{iy
MM NGjEVHhMcW6jc3WgZZN{[Xl? NF21N|hqdmirYnn0d{BXTUeILXnu[JVk\WRicHjvd5Bpd3K7bHH0bY9vKG:oIH\seFE> NFS5flYyPzF4NEOzNi=>
MM.1S NX\TfoVsT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MVuxNEDPxGdxbVy= NETmcYVqdmirYnn0d{BOVSCFZXzsJGdzd3e2aB?= MoW3NVcyPjR|M{K=
MM.1R NVXKd3I3T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NW[5eHVJOTBizsznM41N NVPIdJhxcW6qaXLpeJMhVU1iQ3XscEBIem:5dHi= Mm\hNVcyPjR|M{K=
RPMI MW\Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? M{Syd|ExKM7:Zz;tUC=> NI\4UY9qdmirYnn0d{BOVSCFZXzsJGdzd3e2aB?= NVfXV4ZbOTdzNkSzN|I>
Dox40 M3WzRWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 M3nCPFExKM7:Zz;tUC=> M2XHcolvcGmkaYTzJG1OKEOnbHygS5Jwf3Sq NX;kWYROOTdzNkSzN|I>
INA-6 MVPHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? M{LtdlExKM7:Zz;tUC=> M3XMUIlvcGmkaYTzJG1OKEOnbHygS5Jwf3Sq MXOxO|E3PDN|Mh?=
OPM2 MWXHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MWixNEDPxGdxbVy= MX7pcohq[mm2czDNUUBE\WyuIFfyc5d1cA>? MkPWNVcyPjR|M{K=
U266 MknZS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? M{LGXFExKM7:Zz;tUC=> M{fqUYlvcGmkaYTzJG1OKEOnbHygS5Jwf3Sq MmfXNVcyPjR|M{K=
MM.1S NXjoTpFI[3m2b4TvfIlkcXS7IHHzd4F6 NXX0cmtCOjBizsznM41N NF36emRqdmirYnn0d{BOVSCFZXzsJHN2en[rdnHs MmraNVcyPjR|M{K=
MM.1R MkLhZ5l1d3SxeHnjbZR6KGG|c3H5 M4\PdVIxKM7:Zz;tUC=> M1rCVYlvcGmkaYTzJG1OKEOnbHygV5Vzfmm4YXy= NHzMXHEyPzF4NEOzNi=>
RPMI NYC2e2dx[3m2b4TvfIlkcXS7IHHzd4F6 MWeyNEDPxGdxbVy= MXPpcohq[mm2czDNUUBE\WyuIGP1dpZqfmGu NF:weYYyPzF4NEOzNi=>
Dox40 MV\jfZRwfG:6aXPpeJkh[XO|YYm= MUKyNEDPxGdxbVy= Moi5bY5pcWKrdIOgUW0hS2WubDDTeZJ3cX[jbB?= Mo\MNVcyPjR|M{K=
INA-6 MXHjfZRwfG:6aXPpeJkh[XO|YYm= MnXMNlAh|rypL33M NULNcVBocW6qaXLpeJMhVU1iQ3XscEBUfXK4aY\hcC=> M4\NUVE4OTZ2M{Oy
OPM2 M{HIeYN6fG:2b4jpZ4l1gSCjc4PhfS=> M4PYSlIxKM7:Zz;tUC=> M33GZ4lvcGmkaYTzJG1OKEOnbHygV5Vzfmm4YXy= NUPGRXJyOTdzNkSzN|I>
U266 NFHzPVdkgXSxdH;4bYNqfHliYYPzZZk> MneyNlAh|rypL33M MWTpcohq[mm2czDNUUBE\WyuIGP1dpZqfmGu NXy1V2NWOTdzNkSzN|I>
MM.1S M3u2OGZ2dmO2aX;uJIF{e2G7 NHficGJ{fXCycnXzd4V{KF[HR1[tTY5lfWOnZDDFcoRwfGinbHnhcEBE\WyuIGDyc4xq\mW{YYTpc44h[W6mIF3p[5JifGmxbj6= NFf0[GYyPzF4NEOzNi=>
MM.1R MXzGeY5kfGmxbjDhd5NigQ>? M1nuSpN2eHC{ZYPz[ZMhXkWJRj3JcoR2[2WmIFXu[I91cGWuaXHsJGNmdGxiUILvcIln\XKjdHnvckBidmRiTXnndoF1cW:wLh?= M2Ha[FE4OTZ2M{Oy
Dox40 MkPrSpVv[3Srb36gZZN{[Xl? M2H5SZN2eHC{ZYPz[ZMhXkWJRj3JcoR2[2WmIFXu[I91cGWuaXHsJGNmdGxiUILvcIln\XKjdHnvckBidmRiTXnndoF1cW:wLh?= MYOxO|E3PDN|Mh?=
OPM2 Mm\DSpVv[3Srb36gZZN{[Xl? NHTr[29{fXCycnXzd4V{KF[HR1[tTY5lfWOnZDDFcoRwfGinbHnhcEBE\WyuIGDyc4xq\mW{YYTpc44h[W6mIF3p[5JifGmxbj6= NYHSOI5qOTdzNkSzN|I>
HBMEC NVfhb|lmT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= M1nuNp4yOCEQvF2= NF7ldWdFVVOR MWTJR|UxRTFizszN NHnSNGgzOTB6MU[1Oi=>
HBMEC M{DybGZ2dmO2aX;uJIF{e2G7 MnfrglEh|ryP NXrsV3FKTE2VTx?= NXzIVVF7[WK{b3fheIV{KHSqZTDwbI9{eGixconsZZRqd25ib3[gWmVITlJ{IIfpeIgh\Gm|coXweIlwdiCxZjDkc5dve3S{ZXHtJHBNS87|MR?= MVyyNVA5OTZ3Nh?=
HBMEC M1j0UGZ2dmO2aX;uJIF{e2G7 MmDQglEh|ryP M3;GOGROW09? MUjkbZNzfXC2czD0bIUhWmG|LWLh[k1GWkticHH0bJdigSC2aILveYdpKGSnY4LlZZNm\CCyaH;zdIhwenmuYYTl[EBOTUtzL{KgZY5lKEWUS{GvNi=> NF62bm4zOTB6MU[1Oi=>
HBMEC M1:5e2Z2dmO2aX;uJIF{e2G7 M2LiOJ4zOCEQvF2= MoTXSG1UVw>? NH3wNZZlcXO{dYD0d{A2OCVib3[geJVj\SCob4LtZZRqd25iYYSgNUDPxE1? NX7ZXnlxOjFyOEG2OVY>
MDA-MB-231 M4XTSGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MmXnglExKM7:TR?= NWDFd5hJTE2VTx?= M1fEcWlEPTB;NTFOwG0> MkfVNlExQDF4NU[=
MDA-MB-231 Mn;CSpVv[3Srb36gZZN{[Xl? MkLyNE42KM7:TR?= MWjEUXNQ MmrsbY5pcWKrdIOgeIhmKEWUS{GvNkB{cWewYXzpcocheGG2aIfhfS=> NIXDeoQzOTB6MU[1Oi=>
MDA-MB-231 M4nNPWZ2dmO2aX;uJIF{e2G7 MUK1JO69VQ>? NVnMVlB4TE2VTx?= MWDpcoR2[2W|IHGgZ4VtdC2leXPs[UBienKnc4S= MX[yNVA5OTZ3Nh?=
J82 M{T6OYN6fG:2b4jpZ4l1gSCjc4PhfS=> NVXHe|dYhjFyIN88US=> MnvlSG1UVw>? NGSzPJFKSzVyPUK0MlU4KM7:TR?= MWeyNVUzQTlyMB?=
T24 NW\FSmY3[3m2b4TvfIlkcXS7IHHzd4F6 NF7peGt,OTBizszN Ml;QSG1UVw>? Ml3ITWM2OD13Mj60OUDPxE1? MoK3NlE2Ojl7MEC=
HT1376 NV7G[Wsx[3m2b4TvfIlkcXS7IHHzd4F6 NWTYcZhGhjFyIN88US=> Ml;YSG1UVw>? NGPVOGRKSzVyPUK4MlIyKM7:TR?= M3PNT|IyPTJ7OUCw
RT4 M4rJfoN6fG:2b4jpZ4l1gSCjc4PhfS=> MkW3glExKM7:TR?= M4rHfGROW09? NUjNepNvUUN3ME21MlE1KM7:TR?= NITubJQzOTV{OUmwNC=>
CRL1749 M2ryNoN6fG:2b4jpZ4l1gSCjc4PhfS=> Mn[5glExKM7:TR?= M{ixVmROW09? NXqxdIQ2UUN3ME2yNk43QSEQvF2= NXP0TWVHOjF3Mkm5NFA>
HTB9 M1X6XoN6fG:2b4jpZ4l1gSCjc4PhfS=> MoTxglExKM7:TR?= NUeySmNnTE2VTx?= NHTaU5lKSzVyPUGxMlg1KM7:TR?= Mkf6NlE2Ojl7MEC=
Sup NWPzTlN[[3m2b4TvfIlkcXS7IHHzd4F6 NXfQNol1hjFyIN88US=> NXHqSJV7TE2VTx?= Mmf5TWM2OD13Mz6zNkDPxE1? MXyyNVUzQTlyMB?=
HTB3 MoTpZ5l1d3SxeHnjbZR6KGG|c3H5 MlnEglExKM7:TR?= MXzEUXNQ NFHLbm1KSzVyPUG0MlE3KM7:TR?= MYKyNVUzQTlyMB?=
CEC NGf2d|hHfW6ldHnvckBie3OjeR?= NETqN|B,OTBizsznM41N NXjwOZVlTE2VTx?= MX\kc5dvNXKnZ4XsZZRmeyCYRVfGJIxmfmWucx?= MkX5NlE3OjB6MkK=
RPE MXXGeY5kfGmxbjDhd5NigQ>? MnjQglExKM7:Zz;tUC=> NW\BVItXTE2VTx?= M3TrT4Rwf25vcnXneYxifGW|IG\FS2YhdGW4ZXzz M{\KZ|IyPjJyOEKy
CEC M1HVZ2Z2dmO2aX;uJIF{e2G7 MWr+OUDPxGdxbVy= NHT6dZFFVVOR MUDicI9kc3NiZX7kc5Rp\WyrYXygZ4VtdCCvaXfyZZRqd25? Ml3kNlE3OjB6MkK=
5637 NVnxWWxkT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= M4P0ZmROW09? MV;JR|UxRTF3LkFihKnPxE1? MnT2NlM5QDd4MEW=
J82 NIDxS3NIem:5dHigbY5pcWKrdH;yfUBie3OjeR?= M1Sx[WROW09? MmrETWM2OD1zOD605qCK|ryP NH3LUVAzOzh6N{[wOS=>
5637 NGfk[WtCfXSxcHjh[5kh[XO|YYm= MkTiNlAh|ryP NYj3W5VwTE2VTx?= Mo\seJJq\2encoOgeIhmKGG3dH;wbIFocWNicILvZ4V{ew>? NGn5SXAzOzh6N{[wOS=>
J82 MU\BeZRweGijZ4mgZZN{[Xl? M3ewbVIxKM7:TR?= M1LX[WROW09? NUi3S5NrfHKrZ3fldpMhfGinIHH1eI9xcGGpaXOgdJJw[2W|cx?= MWmyN|g5PzZyNR?=
5637 Ml:5SpVv[3Srb36gZZN{[Xl? M13ENlIxKM7:TR?= MojFSG1UVw>? Mm\pbY5lfWOnczDsfZNwe2:vYXyt[IVx\W6mZX70JI5m[3Kxc3nz NHHiUJgzOzh6N{[wOS=>
J82 NIXQR41HfW6ldHnvckBie3OjeR?= MVOyNEDPxE1? M1XIcmROW09? M3fnT4lv\HWlZYOgcJl{d3OxbXHsMYRmeGWwZHXueEBv\WO{b4Ppdy=> NWHPe5VPOjN6OEe2NFU>
5637 MXnGeY5kfGmxbjDhd5NigQ>? MXmyNEDPxE1? MWHEUXNQ NUTsXnpPcW6mdXPld{BtgXOxc3;t[UBidHSncnH0bY9vKGGwZDDpcohq[mm2czDDRkBi[3Srdnn0fS=> M3n3Z|I{QDh5NkC1
J82 NFiyfnZHfW6ldHnvckBie3OjeR?= M2TEPVIxKM7:TR?= M4iwb2ROW09? M3;JPYlv\HWlZYOgcJl{d3OxbXWgZYx1\XKjdHnvckBidmRiaX7obYJqfHNiQ1KgZYN1cX[rdIm= M3fhVFI{QDh5NkC1
KATO-II NYq0VnBvT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= M3T6eFUh|ryP MmXuSG1UVw>? MmnVZoxw[2u|IIDyc4xq\mW{YYTpc44> NFf6TmczPTJ2OUW1Oy=>
OCUM-2M MonsS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NVv5S|djPSEQvF2= MnziSG1UVw>? MWjicI9kc3NicILvcIln\XKjdHnvci=> MmDKNlUzPDl3NUe=
SNU-16 MVLHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MoqwOUDPxE1? M{\mUGROW09? MYficI9kc3NicILvcIln\XKjdHnvci=> NVriUIRtOjV{NEm1OVc>
HSC-39 M{jQTGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MnXhOUDPxE1? MX7EUXNQ NXjtN2dy[myxY3vzJJBzd2yrZnXyZZRqd25? MXKyOVI1QTV3Nx?=
KATO-II NGL5do1kgXSxdH;4bYNqfHliYYPzZZk> MoHCglExKM7:TR?= MVPEUXNQ NHWyW29KSzVyPUCuNUB1dyB{LkCg{txud2xxTB?= MVyyOVI1QTV3Nx?=
OCUM-2M MkDWZ5l1d3SxeHnjbZR6KGG|c3H5 M1W5[Z4yOCEQvF2= NVnxSJdxTE2VTx?= NVLVWotGUUN3ME2wMlEhfG9iMj6wJO69dW:uL1y= NHLwRo0zPTJ2OUW1Oy=>
SNU-16 MmnqZ5l1d3SxeHnjbZR6KGG|c3H5 M2eyZ54yOCEQvF2= NVP2UGwxTE2VTx?= MX\JR|UxRTBwMTD0c{AzNjBizsztc4wwVA>? NVrQXlFlOjV{NEm1OVc>
HSC-39 MXXjfZRwfG:6aXPpeJkh[XO|YYm= M2jTZp4yOCEQvF2= NFHRVZNFVVOR NFPNcoVKSzVyPUCuNUB1dyB{LkCg{txud2xxTB?= NV20SGdLOjV{NEm1OVc>
NIH 3T3 M{TX[Gdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 MlmzglExKM7:TR?= MYHEUXNQ NXT1R4lvcW6qaXLpeJMh[2WubDDndo94fGhiYX7kJINwdG:weTDmc5Ju[XSrb36= NF3IOZIzPTJ2OUW1Oy=>
KATO-III MUjGeY5kfGmxbjDhd5NigQ>? M1\vUVEh|ryP M4iwU2ROW09? M2Xtb4lv\HWlZYOgZ4VtdC2leXPs[UBienKnc4S= M2HFZ|I2OjR7NUW3
OCUM-2M MWLGeY5kfGmxbjDhd5NigQ>? NH\CZnQyKM7:TR?= NWrMS2hxTE2VTx?= NGHrT4pqdmS3Y3XzJINmdGxvY4njcIUh[XK{ZYP0 NWG1TmNLOjV{NEm1OVc>
KATO-III MnnpRZBweHSxc3nzJIF{e2G7 NY[yTJFmOSEQvF2= NIPqTW1FVVOR MmnPbY5lfWOnczDhdI9xfG:|aYO= M17xXlI2OjR7NUW3
OCUM-2M M2TVVGFxd3C2b4Ppd{Bie3OjeR?= M3foUVEh|ryP NH7KfnNFVVOR NGXsVVZqdmS3Y3XzJIFxd3C2b4Ppdy=> MoPyNlUzPDl3NUe=
KATO-III M2HNdGZ2dmO2aX;uJIF{e2G7 Ml7FNUDPxE1? NGnCfFlFVVOR MXLpcohq[mm2czDGS2ZTOiCyaH;zdIhwenmuYYTpc44h[W6mIHTve45{fHKnYX2gd4lodmGuaX7nJI1wdGWldXzldy=> MV6yOVI1QTV3Nx?=

... Click to View More Cell Line Experimental Data

In vivo The mice treated with 30 mg/kg or 100 mg/kg Pazopanib reveals a significant decrease in tumor burden compared with the mice treated with vehicle or 10 mg/kg Pazopanib. Treatment with Pazopanib is well-tolerated and there is no significant difference in the body weight among the mice in each group. [2]

Protocol

Kinase Assay
+ Expand

Kinase enzyme assays:

VEGFR enzyme assays for VEGGR1, VEGFR2, and VEGFR3 are run in homogeneous time-resolved fluorescence (HTRF) format in 384-well microtiter plates using a purified, baculovirus-expressed glutathione-S-transferase (GST) fusion protein encoding the catalytic c-terminus of human VEGFR receptor kinases 1, 2, or 3. Reactions are initiated by the addition of 10 μL of activated VEGFR2 kinase solution [final concentration, 1 nM enzyme in 0.1 M HEPES, pH 7.5, containing 0.1 mg/mL bovine serum albumin (BSA), 300 μM dithiothreitol (DTT)] to 10 μL substrate solution [final concentration, 360 nM peptide, (biotin-aminohexyl-EEEEYFELVAKKKK-NH2), 75 μM ATP, 10 μM MgCl2], and 1 μL of titrated Pazopanib in DMSO. Plates are incubated at room temperature for 60 min, and then the reaction is quenched by the addition of 20 μL of 100 mM ethylene diamine tetraacetic acid (EDTA). After quenching, 20 μL HTRF reagents (final concentration, 15 nM Streptavidin-linked allophycocyanin, 1 nM Europium-labeled antiphosphotyrosine antibody diluted in 0.1 mg/mL BSA, 0.1 M HEPES, pH 7.5) is added and the plates incubated for a minimum of 10 min. The fluorescence at 665 nM is measured with a Wallac Victor plate reader using a time delay of 50 μs.
Cell Research
+ Expand
  • Cell lines: HUVEC cells
  • Concentrations: 0-10 μM
  • Incubation Time: 1 hour
  • Method:

    Phosphorylation of VEGFR2 is assessed in HUVEC stimulated with VEGF. HUVEC are plated in type-I collagen-coated 10 cm plates in Clonetics EGM-MV medium at 1.0-1.5 × 106 cells/plate. After 24 hours, the confluent cells are serum starved overnight by replacing the growth medium with Clonetics EBM medium containing 0.1% BSA, 500 μg/mL hydrocortisone. Cells are treated with Pazopanib at various concentrations for 1 hour, followed by addition of 10 ng/mL VEGF or vehicle for 10 min. Cells are solubilized in lysis buffer. VEGFR2 is immunoprecipitated using antiflk-1 antibody and analyzed by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) followed by Western blotting and detection with antiflk-1 or with antiphosphotyrosine (anti-P-tyr-biotin) antibody. The VEGFR2 phosphorylation level is quantified by densitometry and normalized to the total VEGFR2 level.


    (Only for Reference)

Solubility (25°C)

In vitro DMSO 17 mg/mL (35.86 mM)
Water <1 mg/mL
Ethanol <1 mg/mL
In vivo 30% PEG400+0.5% Tween80+5% propylene glycol 30 mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 473.98
Formula

C21H23N7O2S.HCl

CAS No. 635702-64-6
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02342600 Not yet recruiting Gastrointestinal Stromal Tumors Sarcoma Alliance for Research through Collaboration|Novartis January 2017 Phase 2
NCT02810756 Not yet recruiting Pharmacokinetics of Pazopanib The Netherlands Cancer Institute September 2016 Phase 0
NCT02348398 Not yet recruiting Cervical Cancer M.D. Anderson Cancer Center|GlaxoSmithKline August 2016 Phase 2
NCT02795819 Recruiting Renal Cell Carcinoma|Soft Tissue Sarcoma|Metastatic Disease Virginia Commonwealth University|Arno Therapeutics|National Cancer Institute (NCI) July 2016 Phase 1
NCT02691767 Not yet recruiting Refractory Solid Tumors Samsung Medical Center May 2016 --
NCT02729194 Not yet recruiting Carcinoma, Renal Cell University of Michigan Cancer Center April 2016 Phase 0

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

VEGFR Signaling Pathway Map

VEGFR Inhibitors with Unique Features

Related VEGFR Products

Tags: buy Pazopanib HCl (GW786034 HCl) | Pazopanib HCl (GW786034 HCl) supplier | purchase Pazopanib HCl (GW786034 HCl) | Pazopanib HCl (GW786034 HCl) cost | Pazopanib HCl (GW786034 HCl) manufacturer | order Pazopanib HCl (GW786034 HCl) | Pazopanib HCl (GW786034 HCl) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID